8-K: Vivani Medical to Merge with ClearOne

Sentiment:

Merger Agreement 7 July 2026 7:46 AM

Vivani Medical, Inc. announced a definitive agreement to merge its subsidiary Cortigent, Inc. with ClearOne, Inc., creating a combined entity with a focus on future growth.

Capital raiseClearOne intends to raise a minimum of $10,000,000 and a maximum of $15,000,000 through the issuance of not less than 2,500,000 and not more than 5,000,000 units.Each unit will consist of one share of ClearOne common stock and one warrant to purchase one share of ClearOne common stock at an exercise price of $10.00 per share, exercisable for six months.

Summary

Vivani Medical, Inc. has entered into a definitive agreement to merge its wholly-owned subsidiary, Cortigent, Inc., with ClearOne, Inc. (ClearOne).
Cortigent will merge with ClearOne's subsidiary, MergerSub, and become a wholly-owned subsidiary of ClearOne.
Vivani Medical will receive 12,500,000 shares of ClearOne common stock as merger consideration.
ClearOne plans to raise between $10,000,000 and $15,000,000 through the issuance of units, each consisting of one share of common stock and one warrant.
The combined company's board of directors is expected to consist of five members, with four designated by Vivani Medical and one by ClearOne stockholders.
Vivani Medical shareholders will have their shares locked up for one to two years following the closing of the merger.
The merger is subject to customary closing conditions, including stockholder approvals and the successful completion of ClearOne's financing.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a strategic move for Vivani Medical to combine with a publicly traded entity and secure potential future capital, though significant risks and uncertainties remain regarding the financing and integration.

Positives

Vivani Medical will receive a significant equity stake in the combined entity (12,500,000 shares of ClearOne common stock).
The merger provides a path for ClearOne to raise capital through a financing round, potentially strengthening its financial position.
Vivani Medical will have substantial representation on the combined company's board of directors (four out of five members).
The transaction is structured to qualify as a tax-free reorganization for U.S. federal income tax purposes.
ClearOne's common stock is expected to remain listed on The Nasdaq Capital Market.

Negatives

Vivani Medical shareholders will receive shares in ClearOne, and the value of these shares is subject to market fluctuations and the dilutive effect of ClearOne's financing.
Vivani Medical's shares will be subject to a lock-up period of one to two years.
The merger is contingent on ClearOne successfully completing its financing round, which could impact the transaction's completion.
The filing mentions potential risks related to the market price of Vivani's stock relative to the value of the consideration shares.

Risks

Failure to satisfy closing conditions, including obtaining necessary stockholder approvals or completing the financing.
Uncertainty regarding the timing of the transaction and financing.
Risks related to ClearOne's continued listing on Nasdaq and the combined company's ability to remain listed.
Potential negative impact on business relationships, operating results, and general business due to the announcement or pendency of the merger.
Costs associated with the merger and potential unexpected expenses.
Market fluctuations in the price of ClearOne's stock and the dilutive effect of ClearOne's planned financing.
The possibility that Vivani's shareholders may own less of the combined company than currently anticipated.
Inability of the combined company to obtain sufficient additional capital to advance product development.
Potential adverse reactions or changes to business relationships, operating results, and business generally resulting from the announcement or completion of the transaction.

Future Outlook

ClearOne plans to raise between $10 million and $15 million through a financing round. The combined company's future operations, including research and development, are expected to focus on the development and commercial potential of its products and services. The company anticipates a certain cash position at closing and a defined cash runway.

Management Comments

Adam Mendelsohn, Ph.D., Vivani President and CEO: 'The new agreement announced today supporting our semaglutide implant program in chronic weight management demonstrates Novo Nordisk's interest in evaluating our technology and its lead semaglutide application. This agreement reinforces our confidence regarding the market opportunity for our GLP-1 implants under development. We believe that our NanoPortal implants under development, including NPM-139, could address a growing segment of patients who would prefer a convenient onceor twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary.'
Vivani expects to initiate a Phase 1 study evaluating NPM-139 in mid-2026.

Industry Context

StockSavvy.ai notes that this merger activity reflects ongoing consolidation trends within the biopharmaceutical sector, particularly for companies focused on novel drug delivery platforms like Vivani's NanoPortal technology. The collaboration with Novo Nordisk for NPM-139 highlights the potential for Vivani's technology in the competitive weight management market, a sector experiencing significant growth and innovation.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Board of Directors	Not specified	Four members designated by Vivani Medical, one by ClearOne stockholders	Effective Time of Merger	As part of the merger agreement.
Chairperson of the Board	Not specified	Designated by Vivani Medical	Effective Time of Merger	As part of the merger agreement.
Chief Executive Officer	Not specified	Designated by Vivani Medical	Effective Time of Merger	As part of the merger agreement.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	The Board of Directors of the combined company will consist of five members, with four designated by Vivani Medical (one serving as Chairperson) and one designated by ClearOne stockholders.	Effective Time of Merger	Increases Vivani Medical's influence on the combined entity's strategic direction and governance.
Equity Moratorium	Restrictions on Parent's ability to issue new equity securities for a period of 12 months post-closing, with certain exceptions.	Closing Date	Aims to protect the ownership stake of existing ClearOne stockholders (Pre-Closing Parent Stockholders) from dilution.
Voting Agreements	Vivani Medical and certain ClearOne shareholders have entered into voting support agreements to ensure approval of the merger and related matters.	Effective Time of Merger	Secures necessary shareholder support for the transaction.
Lock-Up Agreements	Vivani Medical has agreed to customary lock-up restrictions on the Consideration Shares received in the transaction, with 50% locked for one year and 50% for two years.	Closing Date	Limits the immediate resale of Vivani's shares in the combined entity, potentially stabilizing the stock price.

Stakeholder Impact

Shareholders of Vivani Medical will become shareholders of ClearOne, subject to lock-up periods and market risks associated with ClearOne's stock.
ClearOne shareholders will see their company merge with Vivani's subsidiary, with a significant change in board composition and potential dilution from financing.
Employees of Vivani Medical and ClearOne may experience changes in roles and responsibilities within the combined entity.
Creditors and suppliers will continue to engage with the combined entity, with the financial health of ClearOne post-financing being a key factor.

Next Steps

ClearOne to file a registration statement on Form S-1 for the financing.
ClearOne to file a definitive information statement on Schedule 14C.
Vivani Medical to initiate a Phase 1 study for NPM-139 in mid-2026.
Obtain necessary stockholder approvals from both Vivani Medical and ClearOne.
Satisfy all other closing conditions outlined in the merger agreement.

Key Dates

Date	Description
2026-07-01	Date of the Merger Agreement.
2026-12-28	Termination date for the Merger Agreement if not completed.
2026-07-07	Date of the press release announcing the agreement with Novo Nordisk.

Recommendation

hold

The merger presents a strategic combination with potential benefits for Vivani Medical shareholders, including equity in the combined entity and board representation. However, the reliance on ClearOne's financing, the lock-up periods, and the inherent market risks associated with ClearOne's stock warrant a cautious 'hold' stance until the transaction closes and the combined entity's performance becomes clearer.

Keywords

Vivani Medical, ClearOne, Merger Agreement, Cortigent, Merger, SEC Filing, Form 8-K, Financing, Nasdaq, Corporate Governance, Stockholder Approval

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.